MedTrace Logo

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

NCT04497168 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2026-03-16

No results posted yet for this study

Summary

This Parkinson disease (PD) trial will test whether 26 months of citalopram, compared to placebo, can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of the brain linked to visuospatial cognitive impairment in PD.

Conditions

  • Parkinson Disease

Interventions

DRUG

Citalopram 20mg

20mg daily

DRUG

Placebo

matching placebo pills

Sponsors & Collaborators

Principal Investigators

  • Vikas Kotagal, MD · University of Michigan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2026-03-02
Completion
2026-03-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04497168 on ClinicalTrials.gov